Biofrontera : appoints Christoph Dünwald as Chief Commercial Officer

Biofrontera AG / Biofrontera appoints Christoph Dünwald as Chief Commercial Officer . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Leverkusen, 22 July 2015 - Biofrontera (FSE/AIM:B8F), the biopharmaceutical company focusing on sun-induced skin cancer announces the appointment of  Christoph Dünwald (47) as Chief Commercial Officer (CCO). Mr. Dünwald will lead the sales and marketing of the Group as a member of the management board, which he is envisaged to join with effect from 16 November 2015, due to an existing non-compete clause.

Mr. Dünwald brings 24 years of comprehensive sales and marketing expertise in the healthcare sector which he gained working for pharmaceutical businesses in Europe, Asia Pacific and the US.

Christoph Dünwald began his professional career at Bayer, where he worked for 15 years in positions of increasing responsibility in Marketing in both Spain and the US, as well as in Strategic Management positions in Germany and Asia Pacific. He then oversaw Bayer's Healthcare Diagnostics Division in Belgium and Luxembourg as a General Manager.

Following two years as International Sales and Marketing Director for Corporacion Dermoestetica in Spain and the UK he moved on to the US pharmaceutical company Allergan. At Allergan he initially worked as Senior Commercial Director in London until he was assigned the responsibility for Allergan's Medical Business Unit in Spain and Portugal. This position included responsibility for the cooperation between Allergan and Biofrontera and enabled the successful commercial launch of Ameluz^® in Spain.

Jürgen Baumann, Chairman of the Supervisory Board of Biofrontera AG commented: "2016 will be key for the future of Biofrontera with the expected approvals of Ameluz^® for basal cell carcinoma in Europe and actinic keratosis in the US, in Switzerland and in Israel. With these challenges ahead we believe an extension of the Management Board will be crucial for success. We are very glad to announce the appointment of Christoph Dünwald, an internationally very experienced Chief Commercial Officer. He is the ideal person to shape the internationalization of our sales activities and in particular a successful commercial launch of our products in the US."

Christoph Dünwald, future Chief Commercial Officer, added: "Biofrontera has accomplished outstanding achievements with the approval of Ameluz^® in the EU and the filing of the FDA application in the US. I very much look forward to contributing to the successful international commercialization and helping to further deliver outstanding value for shareholders."

Ends

Enquiries, please contact:

Background:

Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz^®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz^® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos^® dermatological range of cosmetics. Belixos^® products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos^® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com:
http://www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.